| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/30/2006 | EP1695978A1 Nucleic acid ligands |
| 08/30/2006 | EP1695977A2 Spiro [isobenzofuran-1,4'piperidin]-3-ones and 3H-spiroisobenzofuran-1, 4'-piperidines |
| 08/30/2006 | EP1695975A1 Stable crystalline salts of 5-methyltetrahydrofolic acid |
| 08/30/2006 | EP1695974A1 1,8-Naphthyridines as CRF antagonists |
| 08/30/2006 | EP1695973A1 Ocaperidone salt and pharmaceutical compositions containing the same |
| 08/30/2006 | EP1695972A1 Process for producing 2-acylthiophene compound |
| 08/30/2006 | EP1695971A1 Substituted phenyl-piperazine compounds, their preparation and use in medicaments |
| 08/30/2006 | EP1695970A1 Peptides useful for competitive modulation of dipeptidyl peptidase IV catalysis |
| 08/30/2006 | EP1695968A1 The glucagon-like peptide-1 receptor agonists, the preparation and the use of the same |
| 08/30/2006 | EP1695966A1 Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| 08/30/2006 | EP1695965A1 Crystalline form beta of the chlorhydrate of ivabradine, process for its preparation and pharamcetuical composition containing it |
| 08/30/2006 | EP1695964A1 Quinoline derivatives for use as intermediates in the synthesis of heterocyclylalcoyl piperidines |
| 08/30/2006 | EP1695962A1 Cyclic amine derivative having heteroaryl ring |
| 08/30/2006 | EP1695961A1 Urea derivative, process for producing the same, and use |
| 08/30/2006 | EP1695959A1 Compouds and methods for the inhibition of the expression of VCAM-1 |
| 08/30/2006 | EP1695957A1 Crystalline forms of (1RS,3RS,6RS)-6-Dimethylaminomethyl-1-(3-methoxy-phenyl)cyclohexane-1,3-diol hydrochloride |
| 08/30/2006 | EP1695955A1 Compounds having lysophosphatidic acid receptor antagonism and uses thereof |
| 08/30/2006 | EP1695716A2 Medicinal compositions containing diuretics and insulin sensitizers |
| 08/30/2006 | EP1695713A1 Enteropathy ameliorating composition |
| 08/30/2006 | EP1695712A2 Oral formulations for the selective inhibition of thrombin comprising boronic acid species |
| 08/30/2006 | EP1695711A2 Parenteral formulations comprising boronic acid species for selective thrombin inhibition |
| 08/30/2006 | EP1695710A1 Crystalline form beta-d fo the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it |
| 08/30/2006 | EP1695709A1 Crystalline form gamma-d of the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it |
| 08/30/2006 | EP1695708A2 Pharmaceutical composition |
| 08/30/2006 | EP1695707A1 Nail varnish containing tazarotene and use thereof for treating and/or preventing psoriasis |
| 08/30/2006 | EP1695706A1 Medicinal compositions and combinations |
| 08/30/2006 | EP1695705A1 Compounds effecting glucokinase |
| 08/30/2006 | EP1695704A1 Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia |
| 08/30/2006 | EP1695703A2 Anticonvulsant amino acids for the treatment of pain |
| 08/30/2006 | EP1695702A2 Treatment of metastatic disease |
| 08/30/2006 | EP1695701A2 HFA suspension formulations comprising an anticholinergic agent |
| 08/30/2006 | EP1695700A1 Dosage form containing oxycodone and naloxone |
| 08/30/2006 | EP1695699A1 Drug-containing grains and solid preparation containing the grains |
| 08/30/2006 | EP1695698A1 Anti-angiogene compositions and methods of use |
| 08/30/2006 | EP1695697A1 Anti-angiogenic compositions and methods of use |
| 08/30/2006 | EP1695696A1 Liposome |
| 08/30/2006 | EP1695691A2 Foaming composition for hair cleaning and hair treatment |
| 08/30/2006 | EP1695634A1 Sugar containing solid sterol dispersions |
| 08/30/2006 | EP1695094A2 Disintegratable films for diagnostic devices |
| 08/30/2006 | EP1694842A1 Rna amidates and thioamidates for rnai |
| 08/30/2006 | EP1694841A2 Cancer treatment |
| 08/30/2006 | EP1694840A2 Combination therapy associating a tgf-beta antagonist with a chemotherapeutic agent |
| 08/30/2006 | EP1694839A2 Laminin-5 modulators and uses thereof |
| 08/30/2006 | EP1694815A2 Method and antisense compound for potentiating anti-cancer agents |
| 08/30/2006 | EP1694714A2 Low molecular weight polysaccharides having antithrombotic activity |
| 08/30/2006 | EP1694688A1 Vanadium compounds as inhibitors of phosphatases |
| 08/30/2006 | EP1694686A1 Kinase inhibitors |
| 08/30/2006 | EP1694683A2 Synthetic process |
| 08/30/2006 | EP1694676A1 Spiroindoline derivatives having insecticidal properties |
| 08/30/2006 | EP1694674A2 Sulfone substituted imidazo ring ethers |
| 08/30/2006 | EP1694673A1 Novel thiazole derivates |
| 08/30/2006 | EP1694671A2 Quinoxalines useful as inhibitors of protein kinases |
| 08/30/2006 | EP1694670A1 Pyrazine derivatives as effective compounds against infectious diseases |
| 08/30/2006 | EP1694667A2 Polymorphs of 1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3, 3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid hydrochloride and mesalyte salts |
| 08/30/2006 | EP1694664A1 2- ( (2, 3-dihydroxypropyl) aminomethyl) chromane derivatives for use as beta-3 adrenoreceptor agonists in the treatment of urological and inflammatory disorders |
| 08/30/2006 | EP1694663A1 Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder |
| 08/30/2006 | EP1694659A1 Thiadiazoles as cxc- and cc- chemokine receptor ligands |
| 08/30/2006 | EP1694657A1 Compositions comprising an hiv protease inhibitor |
| 08/30/2006 | EP1694656A1 Benzoxazine derivatives and uses thereof |
| 08/30/2006 | EP1694654A2 Substituted triazoles as sodium channel blockers |
| 08/30/2006 | EP1694653A1 Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| 08/30/2006 | EP1694652A1 Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates |
| 08/30/2006 | EP1694650A1 1-n-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them |
| 08/30/2006 | EP1694647A1 Cathepsin cysteine protease inhibitors |
| 08/30/2006 | EP1694645A1 Amlodipine gentisate and a method of its preparation |
| 08/30/2006 | EP1694644A2 N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b |
| 08/30/2006 | EP1694640A1 Anti-cancer agents |
| 08/30/2006 | EP1694638A1 N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof |
| 08/30/2006 | EP1694635A2 HYDROXYPROPYL AMIDES FOR THE TREATMENT OF ALZHEIMER’S DISEASE |
| 08/30/2006 | EP1694629A2 Higher fullerenes useful as radical scavengers |
| 08/30/2006 | EP1694627A2 Novel ligands that are activators of the rar receptors, use in human medicine and in cosmetics |
| 08/30/2006 | EP1694623A2 Practical, cost-effective synthesis of ubiquinones |
| 08/30/2006 | EP1694600A2 High efficiency fullerene-based radical scavengers |
| 08/30/2006 | EP1694410A2 Cyclopropane compounds and pharmaceutical use thereof |
| 08/30/2006 | EP1694363A2 Pegylated small molecules |
| 08/30/2006 | EP1694362A1 Improved parasiticide composition |
| 08/30/2006 | EP1694357A1 Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic |
| 08/30/2006 | EP1694341A1 Use of gallium to treat inflammatory arthritis |
| 08/30/2006 | EP1694340A1 Enoxaparin for the treatment of cancer |
| 08/30/2006 | EP1694339A2 9-desoxoerythromycin compounds as prokinetic agents |
| 08/30/2006 | EP1694338A2 Use of superoxide dismutase mimetics and reductase glutathione in the form of anticancer drugs |
| 08/30/2006 | EP1694337A2 Topical use of halosalicylic acid derivatives |
| 08/30/2006 | EP1694336A2 Oral solid instant-release dosage forms comprising finasteride and an anionic surfactant - methods of manufacturing thereof |
| 08/30/2006 | EP1694335A2 Osteoclastogenesis inhibitors and uses thereof |
| 08/30/2006 | EP1694334A1 Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor |
| 08/30/2006 | EP1694333A2 Methods for reducing body fat using vitamin d compounds |
| 08/30/2006 | EP1694332A2 Treatment of sexual disorders |
| 08/30/2006 | EP1694331A1 Methods for suppressing an immune response or a treating a proliferative disorder |
| 08/30/2006 | EP1694330A2 Vinorelbine derivatives |
| 08/30/2006 | EP1694329A2 Diamine and iminodiacetic acid hydroxamic acid derivates |
| 08/30/2006 | EP1694328A2 Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
| 08/30/2006 | EP1694327A2 Novel m3 muscarinic acetylcholine receptor antagonists |
| 08/30/2006 | EP1694326A1 Novel treatment of irritable bowel syndrome i |
| 08/30/2006 | EP1694325A2 Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses |
| 08/30/2006 | EP1694324A2 Methods for reducing the effects of stress on skin condition |
| 08/30/2006 | EP1694323A2 Methods of treating a disorder |
| 08/30/2006 | EP1694322A2 Use of beta-lapachone for protecting against radiation injury |
| 08/30/2006 | EP1694321A1 Tablets of citalopram hydrobromide |
| 08/30/2006 | EP1694320A1 Use of compositions comprising oleanic acid and ursolic acid for the preparation of a medicament for the treatment of hypersensitivity and hyperreactivity |
| 08/30/2006 | EP1694319A1 Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia |